Ultragenyx Pharmaceutical Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.72 billion, with shareholders equity totaling $-376.00 million.
The company employs approximately 893 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, Ultragenyx Pharmaceutical Inc. reported $730.00 million in revenue, generating net income of $-524.00 million.
Key financial metrics include a P/E ratio of -3.28, a price-to-book (P/B) ratio of -4.57, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker RARE.